 | • レポートコード：MRC2Q12-19192 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、麻疹弱毒生ワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 麻疹弱毒生ワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 麻疹弱毒生ワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 麻疹弱毒生ワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの麻疹弱毒生ワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の麻疹弱毒生ワクチンの売上および2028年までの予測に焦点を当てています。 麻疹弱毒生ワクチンのグローバル主要企業には、GSK、Sanofi-Pasteur、Merck、Pfizer、Serum Institute of India、Novartis、Emergent Biosolutions、Bavarian Nordic、Medimmune、Johnson & Johnson、CSL Limited、Changchun Qijian Biological Products Co., Ltd、Beijing Institute of Biological Products Co., Ltd、Wuhan Institute of Biological Products Co., Ltd、Shanghai Institute of Biological Products Co., Ltd、Lanzhou Institute of Biological Products Co., Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 麻疹弱毒生ワクチン市場は、タイプとアプリケーションによって区分されます。世界の麻疹弱毒生ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 液体、粉体 【アプリケーション別セグメント】 病院、クリニック 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 麻疹弱毒生ワクチン製品概要 - タイプ別市場（液体、粉体） - アプリケーション別市場（病院、クリニック） - 調査の目的 ・エグゼクティブサマリー - 世界の麻疹弱毒生ワクチン販売量予測2017-2028 - 世界の麻疹弱毒生ワクチン売上予測2017-2028 - 麻疹弱毒生ワクチンの地域別販売量 - 麻疹弱毒生ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別麻疹弱毒生ワクチン販売量 - 主要メーカー別麻疹弱毒生ワクチン売上 - 主要メーカー別麻疹弱毒生ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（液体、粉体） - 麻疹弱毒生ワクチンのタイプ別販売量 - 麻疹弱毒生ワクチンのタイプ別売上 - 麻疹弱毒生ワクチンのタイプ別価格 ・アプリケーション別市場規模（病院、クリニック） - 麻疹弱毒生ワクチンのアプリケーション別販売量 - 麻疹弱毒生ワクチンのアプリケーション別売上 - 麻疹弱毒生ワクチンのアプリケーション別価格 ・北米市場 - 北米の麻疹弱毒生ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の麻疹弱毒生ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの麻疹弱毒生ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の麻疹弱毒生ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の麻疹弱毒生ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の麻疹弱毒生ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の麻疹弱毒生ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の麻疹弱毒生ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの麻疹弱毒生ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の麻疹弱毒生ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 GSK、Sanofi-Pasteur、Merck、Pfizer、Serum Institute of India、Novartis、Emergent Biosolutions、Bavarian Nordic、Medimmune、Johnson & Johnson、CSL Limited、Changchun Qijian Biological Products Co., Ltd、Beijing Institute of Biological Products Co., Ltd、Wuhan Institute of Biological Products Co., Ltd、Shanghai Institute of Biological Products Co., Ltd、Lanzhou Institute of Biological Products Co., Ltd ・産業チェーン及び販売チャネル分析 - 麻疹弱毒生ワクチンの産業チェーン分析 - 麻疹弱毒生ワクチンの原材料 - 麻疹弱毒生ワクチンの生産プロセス - 麻疹弱毒生ワクチンの販売及びマーケティング - 麻疹弱毒生ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 麻疹弱毒生ワクチンの産業動向 - 麻疹弱毒生ワクチンのマーケットドライバー - 麻疹弱毒生ワクチンの課題 - 麻疹弱毒生ワクチンの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Live Attenuated Measles Vaccine include GSK, Sanofi-Pasteur, Merck, Pfizer, Serum Institute of India, Novartis, Emergent Biosolutions, Bavarian Nordic and Medimmune, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Live Attenuated Measles Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Live Attenuated Measles Vaccine market. Further, it explains the major drivers and regional dynamics of the global Live Attenuated Measles Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
GSK
Sanofi-Pasteur
Merck
Pfizer
Serum Institute of India
Novartis
Emergent Biosolutions
Bavarian Nordic
Medimmune
Johnson & Johnson
CSL Limited
Changchun Qijian Biological Products Co., Ltd
Beijing Institute of Biological Products Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Lanzhou Institute of Biological Products Co., Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Live Attenuated Measles Vaccine Segment by Type
Liquid
Powder
Live Attenuated Measles Vaccine Segment by Application
Hospital
Clinic
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Live Attenuated Measles Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Live Attenuated Measles Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Live Attenuated Measles Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Live Attenuated Measles Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Live Attenuated Measles Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Live Attenuated Measles Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Live Attenuated Measles Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Sanofi-Pasteur, Merck, Pfizer, Serum Institute of India, Novartis, Emergent Biosolutions, Bavarian Nordic and Medimmune, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Live Attenuated Measles Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Measles Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Live Attenuated Measles Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Live Attenuated Measles Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Liquid
1.2.3 Powder
1.3 Market by Application
1.3.1 Global Live Attenuated Measles Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Live Attenuated Measles Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Live Attenuated Measles Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Live Attenuated Measles Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Live Attenuated Measles Vaccine Sales by Region
2.4.1 Global Live Attenuated Measles Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Live Attenuated Measles Vaccine by Region (2023-2028)
2.5 Global Live Attenuated Measles Vaccine Revenue by Region
2.5.1 Global Live Attenuated Measles Vaccine Revenue by Region (2017-2022)
2.5.2 Global Live Attenuated Measles Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Live Attenuated Measles Vaccine Sales by Manufacturers
3.1.1 Global Top Live Attenuated Measles Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Live Attenuated Measles Vaccine in 2021
3.2 Global Live Attenuated Measles Vaccine Revenue by Manufacturers
3.2.1 Global Live Attenuated Measles Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Live Attenuated Measles Vaccine Revenue in 2021
3.3 Global Live Attenuated Measles Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Live Attenuated Measles Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Live Attenuated Measles Vaccine Sales by Type
4.1.1 Global Live Attenuated Measles Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Live Attenuated Measles Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Live Attenuated Measles Vaccine Revenue by Type
4.2.1 Global Live Attenuated Measles Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Live Attenuated Measles Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Live Attenuated Measles Vaccine Price by Type
4.3.1 Global Live Attenuated Measles Vaccine Price by Type (2017-2022)
4.3.2 Global Live Attenuated Measles Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Live Attenuated Measles Vaccine Sales by Application
5.1.1 Global Live Attenuated Measles Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Live Attenuated Measles Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Live Attenuated Measles Vaccine Revenue by Application
5.2.1 Global Live Attenuated Measles Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Live Attenuated Measles Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Live Attenuated Measles Vaccine Price by Application
5.3.1 Global Live Attenuated Measles Vaccine Price by Application (2017-2022)
5.3.2 Global Live Attenuated Measles Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Live Attenuated Measles Vaccine Market Size by Type
6.1.1 North America Live Attenuated Measles Vaccine Sales by Type (2017-2028)
6.1.2 North America Live Attenuated Measles Vaccine Revenue by Type (2017-2028)
6.2 North America Live Attenuated Measles Vaccine Market Size by Application
6.2.1 North America Live Attenuated Measles Vaccine Sales by Application (2017-2028)
6.2.2 North America Live Attenuated Measles Vaccine Revenue by Application (2017-2028)
6.3 North America Live Attenuated Measles Vaccine Market Size by Country
6.3.1 North America Live Attenuated Measles Vaccine Sales by Country (2017-2028)
6.3.2 North America Live Attenuated Measles Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Live Attenuated Measles Vaccine Market Size by Type
7.1.1 Europe Live Attenuated Measles Vaccine Sales by Type (2017-2028)
7.1.2 Europe Live Attenuated Measles Vaccine Revenue by Type (2017-2028)
7.2 Europe Live Attenuated Measles Vaccine Market Size by Application
7.2.1 Europe Live Attenuated Measles Vaccine Sales by Application (2017-2028)
7.2.2 Europe Live Attenuated Measles Vaccine Revenue by Application (2017-2028)
7.3 Europe Live Attenuated Measles Vaccine Market Size by Country
7.3.1 Europe Live Attenuated Measles Vaccine Sales by Country (2017-2028)
7.3.2 Europe Live Attenuated Measles Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Live Attenuated Measles Vaccine Market Size by Type
8.1.1 Asia Pacific Live Attenuated Measles Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Live Attenuated Measles Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Live Attenuated Measles Vaccine Market Size by Application
8.2.1 Asia Pacific Live Attenuated Measles Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Live Attenuated Measles Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Live Attenuated Measles Vaccine Market Size by Region
8.3.1 Asia Pacific Live Attenuated Measles Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Live Attenuated Measles Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Live Attenuated Measles Vaccine Market Size by Type
9.1.1 Latin America Live Attenuated Measles Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Live Attenuated Measles Vaccine Revenue by Type (2017-2028)
9.2 Latin America Live Attenuated Measles Vaccine Market Size by Application
9.2.1 Latin America Live Attenuated Measles Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Live Attenuated Measles Vaccine Revenue by Application (2017-2028)
9.3 Latin America Live Attenuated Measles Vaccine Market Size by Country
9.3.1 Latin America Live Attenuated Measles Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Live Attenuated Measles Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Type
10.1.1 Middle East and Africa Live Attenuated Measles Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Application
10.2.1 Middle East and Africa Live Attenuated Measles Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country
10.3.1 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Overview
11.1.3 GSK Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GSK Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GSK Recent Developments
11.2 Sanofi-Pasteur
11.2.1 Sanofi-Pasteur Corporation Information
11.2.2 Sanofi-Pasteur Overview
11.2.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi-Pasteur Recent Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Overview
11.3.3 Merck Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Pfizer Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Serum Institute of India
11.5.1 Serum Institute of India Corporation Information
11.5.2 Serum Institute of India Overview
11.5.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Serum Institute of India Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Serum Institute of India Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Overview
11.6.3 Novartis Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Novartis Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Novartis Recent Developments
11.7 Emergent Biosolutions
11.7.1 Emergent Biosolutions Corporation Information
11.7.2 Emergent Biosolutions Overview
11.7.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Emergent Biosolutions Recent Developments
11.8 Bavarian Nordic
11.8.1 Bavarian Nordic Corporation Information
11.8.2 Bavarian Nordic Overview
11.8.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bavarian Nordic Recent Developments
11.9 Medimmune
11.9.1 Medimmune Corporation Information
11.9.2 Medimmune Overview
11.9.3 Medimmune Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Medimmune Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Medimmune Recent Developments
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Corporation Information
11.10.2 Johnson & Johnson Overview
11.10.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Johnson & Johnson Recent Developments
11.11 CSL Limited
11.11.1 CSL Limited Corporation Information
11.11.2 CSL Limited Overview
11.11.3 CSL Limited Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 CSL Limited Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 CSL Limited Recent Developments
11.12 Changchun Qijian Biological Products Co., Ltd
11.12.1 Changchun Qijian Biological Products Co., Ltd Corporation Information
11.12.2 Changchun Qijian Biological Products Co., Ltd Overview
11.12.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
11.13 Beijing Institute of Biological Products Co., Ltd
11.13.1 Beijing Institute of Biological Products Co., Ltd Corporation Information
11.13.2 Beijing Institute of Biological Products Co., Ltd Overview
11.13.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
11.14 Wuhan Institute of Biological Products Co., Ltd
11.14.1 Wuhan Institute of Biological Products Co., Ltd Corporation Information
11.14.2 Wuhan Institute of Biological Products Co., Ltd Overview
11.14.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
11.15 Shanghai Institute of Biological Products Co., Ltd
11.15.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information
11.15.2 Shanghai Institute of Biological Products Co., Ltd Overview
11.15.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
11.16 Lanzhou Institute of Biological Products Co., Ltd
11.16.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
11.16.2 Lanzhou Institute of Biological Products Co., Ltd Overview
11.16.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Live Attenuated Measles Vaccine Industry Chain Analysis
12.2 Live Attenuated Measles Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Live Attenuated Measles Vaccine Production Mode & Process
12.4 Live Attenuated Measles Vaccine Sales and Marketing
12.4.1 Live Attenuated Measles Vaccine Sales Channels
12.4.2 Live Attenuated Measles Vaccine Distributors
12.5 Live Attenuated Measles Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Live Attenuated Measles Vaccine Industry Trends
13.2 Live Attenuated Measles Vaccine Market Drivers
13.3 Live Attenuated Measles Vaccine Market Challenges
13.4 Live Attenuated Measles Vaccine Market Restraints
14 Key Findings in The Global Live Attenuated Measles Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【麻疹弱毒生ワクチンについて】 麻疹弱毒生ワクチンは、麻疹ウイルスの弱毒株を用いて製造されたワクチンであり、麻疹という感染症に対する予防手段として広く使用されています。このワクチンは、ウイルスを弱める技術を用いることで、免疫系に強い刺激を与えつつ、実際の病気を引き起こすリスクを低減しています。 麻疹は、麻疹ウイルスによって引き起こされる非常に感染力の強い病気です。麻疹ウイルスは主に空気中の飛沫を介して感染し、鼻や喉から体内に侵入します。麻疹の症状には、高熱、咳、鼻水、発疹などが含まれ、重症化することもあり、特に小児や免疫力が低下している人々に危険を及ぼすことがあります。世界中で毎年多くの感染者が報告されており、予防接種はこの病気の蔓延を防ぐための最も効果的な手段とされています。 麻疹弱毒生ワクチンの特徴には、まずその製造過程にあります。ワクチンの基本成分は、麻疹ウイルスの弱毒株であり、これは正常な病原体を用いるのではなく、人為的に変異させたり、培養環境で感染力を低下させたりすることで製造されます。この過程によって、ワクチンは体内に投与された場合でも重篤な疾患を引き起こすことはなく、むしろ免疫系を刺激して抗体を生成させる効果があります。 また、麻疹弱毒生ワクチンはその効果が長期間持続する点も特徴的です。ほとんどの場合、1回の接種で数年から数十年にわたって免疫を与えることができます。通常は小児期に接種が推奨されており、多くの国では1歳や3歳の時期に接種が行われます。 このワクチンは、接種後に体内で自己免疫の反応を引き起こすため、短時間で高い抗体価を生成します。初回接種後、通常は数週間で抗体が形成され、その後の感染から身体を守ることができます。さらに、2回目の接種を行うことにより、免疫の効果を補強し、持続性を高めることが可能です。これは、ブースター接種と呼ばれる方法です。 麻疹弱毒生ワクチンは、単独で使用されることもありますが、他のワクチンと組み合わせて投与される場合も多いです。特に、MMRワクチン（麻疹・流行性耳下腺炎・風疹の三種混合ワクチン）が有名です。このように、関連技術としては複数のワクチンを組み合わせて、効率的に広範囲の感染症に対する免疫を獲得できる方法があります。 また、麻疹弱毒生ワクチンには副作用も存在します。一般的には接種後に軽い発熱や発疹が見られることがありますが、重篤な副作用は非常に稀です。麻疹ワクチンが接種された際に、発疹や軽度の病状が現れることは、実際にウイルスに感染した際の症状に似ていますが、これは体が免疫を構築している証拠でもあります。 近年、麻疹のワクチン接種率が低下することによる問題が取り上げられています。ワクチンに対する誤解や不安から接種を避ける人々が増加し、その結果、麻疹の再流行が懸念されています。公衆衛生の観点からは、集団免疫を維持するために、一定の接種率が必要です。接種率が85%を下回ると、集団免疫が失われ、病気の蔓延を防ぐことが難しくなります。 麻疹ワクチンについての最近の研究では、ワクチンの効果をさらに高めるための新しい技術やアプローチが模索されています。例えば、ワクチンの冷凍保存の難しさに対する解決策や、接種方法の改善、さらには新しいワクチンの開発が進められています。これにより、より多くの人々が安心して接種できる環境を整えることが目的とされています。 最後に、麻疹弱毒生ワクチンは、麻疹の予防に非常に効果的な手段であり、世界中の公衆衛生に貢献している重要なワクチンです。その効果的な使用により、麻疹の流行を抑制し、多くの命を守ることができます。今後も、ワクチン接種の重要性を広く伝え、全ての人々がワクチンを受けられるような環境整備が求められます。 |